enzh-TWfrdeitjaptrues

Date: March 12, 2011 Location: 4th International Patient & Physician Summit on WM, Orlando, FL
Lecturer: Thea Ioakimidis, Bing Center for WM Subject: Maintenance Rituximab in WM

Click video player to start video. NOTE: It may take a few minutes for video to load. Use the navigation controls in the PDF viewer to view the corresponding slide in the lecture.

Latest Bing Center News

Great Debates in Hematological Malignancies - 2021

Great Debates in Hematological Malignancies - 2021

We're pleased to announce that registration is now open for the 2021 Great Debates & Updates Conferences. Each meeting will cover the most critical updates occurring in the field, while incorporating a distinct focus on the latest advances and treatment options.

Read more..

A WMer's thoughts around the holidays from her to you....

A WMer's thoughts around the holidays from her to you....

Thanksgiving 2020: Home, but not Alone: Has your sense of time shifted lately?  Does avoiding people feel bizarre, and has Purell become your new best friend?  Do you spot beauty in surprising places, and feel the rhythm of your breath inside your mask?

Read more..

Genomic and Treatment Advances in Waldenstrom's Macroglobulinemia

Genomic and Treatment Advances in Waldenstrom's Macroglobulinemia

On October 21, 2020, Dr. Steven Treon gave a webcast lecture to the Canadian National WMFC Patient Support Group. The main topic was genomic & treatment advances in WM, with the discussion also including the related issues surrounding COVID-19.

Read more..

Treatment Advancements are Improving Survivorship and Prompting Hope

Treatment Advancements are Improving Survivorship and Prompting Hope

Is a cure for Waldenstrom macroglobulinemia on the horizon? In the past several decades Waldenstrom’s survivorship has vastly improved due to safer and more effective treatment drugs. Could this indicate that a cure might be within reach? Patient Power Co-Founder Andrew Schorr speaks with Dr. Steven Treon, director, Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, about his predictions for the future of Waldenstrom macroglobulinemia treatment.

Read more..

IMS Virtual Workshop November 6-7, 2020

IMS Virtual Workshop November 6-7, 2020

Dr. Steven Treon will be giving a lecture on "New Insights into Waldenstrom's in Session 4 of this virtual Workshop. If you are interested in attending, registration will be closing soon.

Read more..

Bing-Neel Support Group/Ask the Doctor meeting: Nov 22, 2020

Bing-Neel Support Group/Ask the Doctor meeting: Nov 22, 2020

The Eastern Massachusetts IWMF Support Group invites WM/Bing-Neel patients and caregivers from across the globe to join us in the first-ever support group meeting focused on this particularly rare WM complication. With Bing-Neel specialists, Dr. Steve Treon and Dr. Jorge Castillo of Dana-Farber Cancer Institute.

Read more..

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

Every two years WM experts from around the world meet to discuss the latest research and developments. The last meeting, IWWM-10 was held in New York in October, 2018, and the consensus recommendations on treatment have just been published in The Lancet. Registration (to read the article) is free.

Read more..

Ibrutinib Demonstrates Long-Term Safety, Activity in Relapsed/Refractory WM

Ibrutinib Demonstrates Long-Term Safety, Activity in Relapsed/Refractory WM

Ibrutinib is a highly active and tolerable therapy for symptomatic, relapsed, or refractory patients with Waldenström macroglobulinemia (WM) and a preferable option for use in previously treated patients, according to a study published in the Journal of Clinical Oncology (2020;JCO2000555. doi:10.1200/JCO.20.00555).

Read more..

The fourth issue of the 21st volume of the IWMF Torch is now online!

The fourth issue of the 21st volume of the IWMF Torch is now online!

If you’ve ever had questions about clinical trials, this issue will help clarify various aspects of them, from both the doctor’s and the patient’s perspectives. It will be obvious that medical as well as personal reasons need to be considered before making the plunge.

Read more..

BTK Inhibitors Transform Waldenström Macroglobulinemia Management

BTK Inhibitors Transform Waldenström Macroglobulinemia Management

BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemi; with 4 agents under examination in the space, selection will depend on availability, toxicity, convenience, and cost.

Read more..